|
N-(3,5-dibromo-4-hydroxyphenyl)benzamide
|
DB08104 |
|
|
Ixekizumab
|
DB11569 |
[Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflammatory conditions. In particular, IL-17A has been found to be implicated in a variety of autoimmune diseases including Rheumatoid Arthritis and plaque psoriasis.
Ixekizumab is produced by recombinant DNA technology in a recombinant mammalian cell line and purified using standard technology for bioprocessing. Ixekizumab is comprised of two identical light chain polypeptides of 219 amino acids each and two identical heavy chain polypeptides of 445 amino acids each, and has a molecular weight of 146,158 Daltons for the protein backbone of the molecule. It is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.] |
|
Octamoxin
|
DB09249 |
[Octamoxin, also known as _2-octylhydrazine_, is both an irreversible and nonselective monoamine oxidase enzyme inhibitor (MAOI) of the _hydrazine_ chemical class. This drug was used in the past as an antidepressant agent in the 1960s, however, has since been discontinued.] |
|
Insulin tregopil
|
DB11568 |
|
|
Insulin peglispro
|
DB11567 |
|
|
Calcitonin eel
|
DB12898 |
[HC-58 has been used in trials studying the prevention of Severe Upper Limb Hemiplegia.] |
|
TT-301
|
DB12899 |
[TT301 has been used in trials studying the treatment of Traumatic Brain Injury.] |
|
Raluridine
|
DB12894 |
[Raluridine has been used in trials studying the treatment of HIV Infections.] |
|
Bicuculline
|
DB11562 |
[Bicuculline is a light-sensitive competitive antagonist of GABAA receptors. It was originally identified in 1932 in plant alkaloid extracts and has been isolated from Dicentra cucullaria, Adlumia fungosa, Fumariaceae, and several Corydalis species.] |
|
Aminacrine
|
DB11561 |
[A highly fluorescent anti-infective dye used clinically as a topical antiseptic and experimentally as a mutagen, due to its interaction with DNA. It is also used as an intracellular pH indicator.] |
|
TD-139
|
DB12895 |
[TD139 has been investigated for the treatment of Idiopathic Pulmonary Fibrosis.] |
|
Lesinurad
|
DB11560 |
[Lesinurad is an oral uric acid transporter 1 (URAT1) inhibitor indicated for the treatment of hyperuricemia associated with gout. It reduces serum uric acid concentration through the inhibition of URAT1, an enzyme responsible for reuptake of uric acid from the renal tubule, and OAT4, another uric acid transporter associated with diuretic-induced hyperuricemia.
Marketed as the product Zurampic, it is indicated for use in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout in
patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone. In August 2017, a combination oral therapy consisting of lesinurad and [DB00437] was FDA-approved under the brand name Duzallo indicated for the treatment of gout-related hyperuricemia in patients with uncontrolled gout.] |
|
PSI-352938
|
DB12896 |
[PSI-352938 has been used in trials studying the treatment of Hepatitis C and Hepatitis C, Chronic.] |
|
MK-7622
|
DB12897 |
[MK-7622 has been used in trials studying the treatment of Alzheimer's Disease.] |
|
Dihydrexidine
|
DB12890 |
[Dihydrexidine has been used in trials studying the treatment of SPD, Cocaine-Related Disorders, and Schizotypal Personality Disorder.] |
|
Ozanezumab
|
DB12891 |
[Ozanezumab has been used in trials studying the treatment of Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis, Relapsing-Remitting.] |
|
Insulin argine
|
DB11564 |
|
|
MGB-BP-3
|
DB12892 |
[Mgb Bp 3 is under investigation in clinical trial NCT02518607 (Safety, Blood Levels and Effects of MGB-BP-3).] |
|
Sacituzumab govitecan
|
DB12893 |
[Sacituzumab govitecan has been used in trials studying the treatment of Breast Cancer, Cervical Cancer, Renal Cell Cancer, Colorectal Cancer, and Esophageal Cancer, among others.] |
|
Sebelipase alfa
|
DB11563 |
[Sebelipase alfa is a recombinant form of the enzyme lysosomal acid lipase (LAL) approved for the treatment of lysosomal acid lipase deficiency (LAL-D). The amino acid sequence for sebelipase alfa is the same as the amino acid sequence for human LAL. Sebelipase alfa is an orphan drug which is expected to cost about $310,000 for annual treatment in the United States. Sebelipase alfa is marketed under the brand name Kanuma™ by Alexion Pharmaceuticals, Inc.] |
